Biotech Co.*
(Country/Symbol)

Pharma Co.
(Country)

Change from original agreement

Disclosed Funding (M)

Terms/Details
(Date)


I. MODIFIED AGREEMENTS

Aclara
BioSciences
Inc.
(ACLA)

The R.W.
Johnson Pharma-
ceutical Research Institute and
Janssen Research Foundation (subsidiaries of Johnson & Johnson)

Extended collaboration providing early access to certain Aclara technologies for drug discovery

ND

RWJPRI and JRF will receive early access to Aclara's eTag assay technology (10/29)

Anadys Pharm-
aceuticals
Inc.*

Aventis Pharma
SA (France)

Extended collaboration to include Anadys' new assay development and screening platform

ND

The companies completed the initial three-year collaboration relating to the identification of novel fungal targets (10/9)

Icagen Inc.*

Bristol-Myers
Squibb Co.

Renewed research and development agreement for discovery and development of small-molecule drugs targeting a specific ion channel involved in atrial fibrillation

ND

The renewal provides for continued research and development funding by Bristol-Myers; the original deal, signed in 1997, was valued at up to $75M (10/22)

IDEC Pharma-
ceuticals
Corp.
(IDPH)

Mitsubishi
Pharma Corp.
(Japan)

Broadened deal to develop the psoriasis monoclonal antibody IDEC-114

$35

Mitsubishi will help pay for clinical development of the drug and will conduct parallel clinical trials in Japan (10/19)

InterMune
Inc.
(ITMN)

Boeheringer
Ingelheim Inter-
national GmbH
(Germany)

Expanded partnership to include the development and commercialization of interferon gamma-1b for the treatment of ovarian cancer

ND

Previous indications were idiopathic pulmonary fibrosis, tuberculosis, systemic fungal infections, chronic granulomatous disease and osteoporosis (10/16)

Kosan
Biosciences
Inc.
(KOSN)

The R.W.
Johnson Pharma-
ceutical Research
Institute and
Ortho-McNeil
Pharmaceutical
Inc. (units of
Johnson
and Johnson)

Extended collaboration to Dec. 28, 2002, in which Kosan is producing novel macrolide antibiotic leads using its technology to genetically engineer microbial biosynthetic pathways

ND

The collaboration agreement was previously scheduled to terminate Dec. 28, 2001 (11/5)

Millennium
Pharmaceu-
ticals
Inc.
(MLNM)

Bayer AG
(Germany)

Expanded $465M 1998 collaboration to include three additional indications

$465

The collaboration will now include drug targets relevant to thrombosis, urinary incontinence and benign prostatic hypertrophy, in addition to cardiovascular disease, cancer, pain, hematology and viral infections; the companies discontinued efforts in osteoporosis and liver fibrosis (9/19)

ViroLogic Inc.
(VLGC)

F. Hoffmann-La
Roche Ltd. and
Trimeris Inc.
(TRMS)

Expanded agreement to use ViroLogic's HIV resistance testing technology

ND

The technology will be used in the development of T-20 and T-1249, members of a class of antiviral agents called fusion inhibitors (10/16)

II. TERMINATED AGREEMENTS

American
Biogenetic
Sciences Inc.
(OTC BB:MABA)

Abbott
Laboratories
Inc.

Terminated rights
agreement for ABS-103

D

American Biogenetic reacquired the license rights for its neurological compound (11/12)

AtheroGenics
Inc.
(AGIX)

Schering-
Plough Corp.

Terminated rights
agreement for AGI-1067

ND

AtheroGenics regained rights to AGI-1067 in order to more rapidly develop the compound (10/5)

CeNeS Pharm-
aceuticals
plc
(UK; LSE:CEN)

Bioglan Pharma
plc (UK)

Terminated development and license agreement for a sublingual opiate spray

ND

CeNeS said it is terminating the agreement because Bioglan has failed to comply with its obligations (11/7**)

Chromos
Molecular
Systems Inc.
(Canada;
TSE:CHR)

Pharming
Technologies
BV (the
Netherlands)

Termination of the research and license agreement

ND

Chromos completed a study required under the agreement to assess the feasibility of applying Chromos' Artificial Chromosome Expression System technology to the production of milk in transgenic animals (10/1)

Infigen Inc.*

Pharming
Holding NV
(the Nether-
lands)

Terminated agreement to commercialize Infigen's transgenic technologies

ND

The termination also means Pharming and its subsidiaries must cease using intellectual property previously licensed by Infigen (10/15)

Neurochem
Inc.
(Canada;
TSE:NRM)

H. Lundbeck
A/S (Denmark)

Terminated partnership to develop a drug for Alzheimer's disease

$13

The collaboration began in November 1999; Neurochem received about $13M from Lundbeck since the collaboration began (10/12)

Oxigene Inc.
(OXGN)

Bristol-Myers
Squibb Co.

Terminated rights
agreement for Oxigene's combretastin family of vascular targeting agents, including CA4P

ND

Bristol-Myers' strategic profile changed when several acquisitions were made; Oxigene regained rights to its agents (10/25)

Zonagen Inc.
(ZONA)

Wyeth-Ayerst
Laboratories
(unit of American
Home Products
Corp.)

Terminated option agreement

ND

Zonagen suspended further research on a zona pellucida-based contraceptive vaccine following inconsistent results from an ongoing baboon study (9/27)


NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange